Exciting Launch of the CGuard Prime Carotid Stent System
InspireMD, Inc. (NASDAQ: NSPR), a pioneering developer in stroke prevention technology, has officially launched the CGuard Prime carotid stent system in the U.S. This significant milestone follows the recent approval from the U.S. Food and Drug Administration (FDA) for its premarket application (PMA). With this launch, InspireMD aims to enhance patient safety and outcomes in carotid interventions.
Key Features of the CGuard Prime System
The CGuard Prime is thoughtfully engineered to address the inherent risks of embolism during carotid interventions. The system incorporates innovative solutions to ensure that embolic materials are contained while preserving blood flow in the external carotid artery. Notably, the device includes several groundbreaking features:
Dual Layer Design
The CGuard Prime's dual-layer design integrates the largest open-cell stent framework combined with the smallest mesh pore size available, optimizing both safety and functionality. This architecture is pivotal in reducing the chances of plaque protrusion and ensuring reliable protection.
MicroNet™ Technology
Another standout feature is the MicroNet™, a unique bio-stable mesh constructed from a single 20 ?m Polyethylene Terephthalate (PET) strand. This technology is designed to capture and seal thrombus and plaque against the vessel wall, providing a necessary barrier against embolization.
SmartFit™ Application
The SmartFit™ technology eliminates the need for tapered stents. Instead, it guarantees precise positioning and apposition against the vessel wall, ensuring optimal performance during procedures.
Statements from InspireMD Leadership
Marvin Slosman, the Chief Executive Officer of InspireMD, expressed great enthusiasm about the U.S. launch, stating, "We’ve invested significant effort in preparing for this moment. Our established commercial team, filled with industry veterans, is ready to make an impactful entry into this market. We believe CGuard Prime will change the landscape of carotid interventions, and we are grateful for everyone supporting us in this journey.”
Expert Insights on Carotid Intervention
Experts in the field have shown strong support for the CGuard Prime system. Dr. D. Chris Metzger, System Vascular Chief at OhioHealth, highlighted the importance of this innovation in the fight against carotid artery disease. "The unique design truly addresses the complexities of carotid artery disease," he noted. His experience with the CGuard Prime during clinical trials reinforces the demand for safer intervention alternatives, particularly for patients at greater stroke risk.
Community Commitment
Alan Levine, Chairman and CEO of Ballad Health, commented on their role in the development of the CGuard Prime system, stating, "We are proud to have been instrumental in the early phases of its journey. Our contributions underscore our dedication to advancing healthcare innovations and providing patients with cutting-edge medical technologies.”
About CGuard Prime and InspireMD
The CGuard Prime carotid stent system represents a significant leap towards ensuring patient safety through sustained embolic protection. By combining an advanced stent frame with robust mesh technology, InspireMD aims to set a new standard in the carotid stenting industry.
InspireMD is committed to harnessing its proprietary MicroNet mesh technology to enhance the quality of care and ensure superior clinical results for patients undergoing carotid interventions. The company’s stock trades on Nasdaq under the ticker symbol NSPR. Investors interested in staying updated on the latest developments can find further information on the company’s website.
Frequently Asked Questions
What is the CGuard Prime Carotid Stent System?
The CGuard Prime Carotid Stent System is a technologically advanced stent designed to reduce the risk of embolism during carotid artery procedures while preserving blood flow in critical areas.
How does the CGuard Prime improve patient outcomes?
Its unique design features, including the MicroNet™ and SmartFit™ technologies, enhance embolic protection and precision in placement, contributing to better surgical results.
Who leads the team behind InspireMD?
Marvin Slosman serves as the Chief Executive Officer, bringing extensive experience and leadership to the company’s initiatives and strategic plans.
What are the key benefits of this new technology?
The CGuard Prime offers improved safety by minimizing embolism risks, ensuring precise vessel wall apposition, and enhancing overall treatment effectiveness for stroke prevention.
How can investors learn more about InspireMD updates?
Investors can visit InspireMD’s official website, where the company shares crucial updates and information that may be beneficial.
